title: Selected serum cytokines in systemic lupus erythematosus treated with quinagolide.
abstract: The objective of this study was to determine the effect of quinagolide (Norprolac) on serum level of cytokines in systemic lupus erythematosus (SLE) patients. In 20 SLE patients treated with a low dose of quinagolide, and in 17 healthy persons who constituted the control group, concentration of serum prolactin (PRL), interleukins (ILs), soluble tumor necrosis factor receptors (sTNF Rs) preceded by calculation of disease activity index (SLEDAI) were tested at entry and then after 3 months in 16 patients and after 6 months in 11 patients who completed the study. Serum PRL level was higher (though insignificantly) in the SLE group than in the controls and decreased significantly after 6 months of therapy. A raised SLEDAI score at entry was significantly reduced during therapy but a weak correlation with PRL level was revealed. A significant increase in IL-6 level in SLE group as compared to controls was observed (respectively 14.57 +/- 13.25 and 5.04 +/- 3.35 microg/ml) as well as a significantly decreased level after 6 months of treatment (4.30 +/- 2.51 pg/ml). There was a significant difference between sTNF RI concentration before and after 3 months of quinagolide treatment (respectively 1140.83 +/- 312.08 and 1454.58 +/- 465.54 pg/ml). After 6 months of treatment a statistically significant correlation between concentration of PRL and level of IL-6 and a negative correlation between PRL and sTNF RI was revealed. Quinagolide treatment may have a role in the management of SLE patients.
authors: Department of Internal Diseases and Clinical Pharmacology, University School of Medicine, Katowice, Poland. genmar@ka.onet.pl
authors: A
authors: A
authors: Hrycek
authors: P
authors: P
authors: Cieślik
authors: J
authors: J
authors: Tustanowski
authors: S
authors: S
authors: Nowak
authors: P
authors: P
authors: Jedynak
mesh_terms: D000328:Adult; D000634:Aminoquinolines / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D011388:Prolactin / Q000097:blood; D011446:Prospective Studies; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism; D012720:Severity of Illness Index
chemical_list: D000634:Aminoquinolines; D018491:Dopamine Agonists; D015850:Interleukin-6; D018124:Receptors, Tumor Necrosis Factor; D016753:Interleukin-10; C046650:quinagolide; D011388:Prolactin